Clinical Trials /

Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT01904643

Description:

This phase I trial studies the side effects and the best dose of lenalidomide when given together with combination chemotherapy in treating patients with relapsed or refractory acute myeloid leukemia. Lenalidomide may stop the growth of acute myeloid leukemia by blocking blood flow to the cancer. Drugs used in chemotherapy, such as mitoxantrone hydrochloride, etoposide, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide and combination chemotherapy may be an effective treatment for acute myeloid leukemia.

Related Conditions:
  • Acute Myeloid Leukemia
Recruiting Status:

Terminated

Phase:

Phase 1

Trial Eligibility

Document

Title

  • Brief Title: Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
  • Official Title: A Phase I Study of Lenalidomide Therapy Prior to Re-induction Chemotherapy With Mitoxantrone, Etoposide, and Cytarabine (MEC) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)

Clinical Trial IDs

  • ORG STUDY ID: HEMAML0024
  • SECONDARY ID: NCI-2013-01349
  • SECONDARY ID: 27313
  • SECONDARY ID: P30CA124435
  • NCT ID: NCT01904643

Conditions

  • Adult Acute Megakaryoblastic Leukemia (M7)
  • Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
  • Adult Acute Monoblastic Leukemia (M5a)
  • Adult Acute Monocytic Leukemia (M5b)
  • Adult Acute Myeloblastic Leukemia With Maturation (M2)
  • Adult Acute Myeloblastic Leukemia Without Maturation (M1)
  • Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
  • Adult Acute Myeloid Leukemia With Del(5q)
  • Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
  • Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
  • Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
  • Adult Acute Myelomonocytic Leukemia (M4)
  • Adult Erythroleukemia (M6a)
  • Adult Pure Erythroid Leukemia (M6b)
  • Recurrent Adult Acute Myeloid Leukemia

Interventions

DrugSynonymsArms
lenalidomideCC-5013, IMiD-1, RevlimidTreatment (lenalidomide, combination chemotherapy)
mitoxantrone hydrochlorideCL 232315, DHAD, DHAQ, NovantroneTreatment (lenalidomide, combination chemotherapy)
etoposideEPEG, VP-16, VP-16-213Treatment (lenalidomide, combination chemotherapy)
cytarabineARA-C, arabinofuranosylcytosine, arabinosylcytosine, Cytosar-U, cytosine arabinosideTreatment (lenalidomide, combination chemotherapy)

Purpose

This phase I trial studies the side effects and the best dose of lenalidomide when given together with combination chemotherapy in treating patients with relapsed or refractory acute myeloid leukemia. Lenalidomide may stop the growth of acute myeloid leukemia by blocking blood flow to the cancer. Drugs used in chemotherapy, such as mitoxantrone hydrochloride, etoposide, and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide and combination chemotherapy may be an effective treatment for acute myeloid leukemia.

Detailed Description

      PRIMARY OBJECTIVES:

      I. To determine the maximum tolerated dose (MTD) of lenalidomide when used in combination
      with mitoxantrone hydrochloride, etoposide, and cytarabine (MEC) in patients with relapsed or
      refractory acute myeloid leukemia (AML).

      II. To determine the dose-limiting toxicities (DLTs) of this combination in this patient
      population.

      SECONDARY OBJECTIVES:

      I. To determine whether the combination of lenalidomide priming prior to re-induction
      chemotherapy with MEC has clinical activity in patients with relapsed or refractory AML.

      OUTLINE: This is a dose-escalation study of lenalidomide.

      LENALIDOMIDE PRIMING: Patients receive lenalidomide orally (PO) for 5 or 7 days.

      RE-INDUCTION CHEMOTHERAPY: Patients receive etoposide intravenously (IV) over 1 hour,
      cytarabine IV over 3 hours, and mitoxantrone hydrochloride IV over 15-30 minutes on days 1-5.
      Patients failing to achieve blast count < 5% at 21 days may receive a second course of
      induction therapy. Patients achieving complete remission proceed to lenalidomide priming.

      LENALIDOMIDE PRIMING: Within 4-6 weeks, patients receive lenalidomide PO for 5 or 7 days and
      then proceed to consolidation therapy.

      CONSOLIDATION CHEMOTHERAPY: Patients receive etoposide IV over 1 hour, cytarabine IV over 3
      hours, and mitoxantrone hydrochloride IV over 15-30 minutes on days 1-4. Treatment repeats
      every 28-35 days for up to 2 courses in the absence of disease progression or unacceptable
      toxicity.

      After completion of study treatment, patients are followed up for 6 months.
    

Trial Arms

NameTypeDescriptionInterventions
Treatment (lenalidomide, combination chemotherapy)ExperimentalLENALIDOMIDE PRIMING: Patients receive lenalidomide PO for 5 or 7 days. RE-INDUCTION CHEMOTHERAPY: Patients receive etoposide IV over 1 hour, cytarabine IV over 3 hours, and mitoxantrone hydrochloride IV over 15-30 minutes on days 1-5. Patients failing to achieve blast count < 5% at 21 days may receive a second course of induction therapy. Patients achieving complete remission proceed to lenalidomide priming. LENALIDOMIDE PRIMING: Within 4-6 weeks, patients receive lenalidomide PO for 5 or 7 days and then proceed to consolidation therapy. CONSOLIDATION CHEMOTHERAPY: Patients receive etoposide IV over 1 hour, cytarabine IV over 3 hours, and mitoxantrone hydrochloride IV over 15-30 minutes on days 1-4. Treatment repeats every 28-35 days for up to 2 courses in the absence of disease progression or unacceptable toxicity.
  • lenalidomide
  • mitoxantrone hydrochloride
  • etoposide
  • cytarabine

Eligibility Criteria

        Inclusion Criteria:

          -  Patients eligible include those with diagnosis of AML other than acute promyelocytic
             leukemia by World Health Organization (WHO) criteria with relapsed disease after
             induction therapy or refractory to induction chemotherapy, as determined by morphology
             on bone marrow biopsy; also eligible are patients unwilling to receive standard
             induction chemotherapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Serum creatinine =< 1.5 mg/dL; if serum creatinine > 1.5 mg/dL, then the estimated
             glomerular filtrate rate (GFR) must be > 60ml/min/1.73m^2 as calculated by the
             Modification of Diet in Renal Disease equation

          -  Serum bilirubin =< 1.5 x upper limit of normal (ULN) unless elevation is considered to
             be secondary to Gilbert's syndrome, hemolysis, or hepatic infiltration by AML

          -  Aspartate transaminase (AST)/alanine transaminase (ALT) =< 2.5 x ULN

          -  Alkaline phosphatase =< 2.5 x ULN

          -  All study participants must be registered into the mandatory Revlimid assistance
             (RevAssist) program, and be willing and able to comply with the requirements of
             RevAssist

          -  Females of childbearing potential (FCBP) must have a negative serum or urine pregnancy
             test with a sensitivity of at least 50 mIU/mL within 10 - 14 days and again within 24
             hours prior to prescribing lenalidomide for cycle 1 (prescriptions must be filled
             within 7 days as required by RevAssist) and must either commit to continued abstinence
             from heterosexual intercourse or begin TWO acceptable methods of birth control, one
             highly effective method and one additional effective method AT THE SAME TIME, at least
             28 days before she starts taking lenalidomide; FCBP must also agree to ongoing
             pregnancy testing; men must agree to use a latex condom during sexual contact with a
             FCBP even if they have had a successful vasectomy

        Exclusion Criteria:

          -  Patient must not undergo concomitant radiotherapy, chemotherapy or immunotherapy;
             patient must not be in concurrent study with other investigational agents

          -  Patients who have received prior lenalidomide therapy are not eligible for this study;
             further there should be at least a 14-day window from the patient's last prior therapy
             before initiation of treatment on clinical trial

          -  Have other severe concurrent disease or serious organ dysfunction involving the heart,
             kidney, liver or other organ system that may place the patient at undue risk to
             undergo treatment

          -  Have significant, uncontrolled active infection

          -  Pregnant or nursing patients will be excluded from the study

          -  Known human immunodeficiency virus (HIV) infection
      
Maximum Eligible Age:N/A
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:MTD of lenalidomide when used in combination with MEC determined by DLT using the Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (CTCAE), version 4.0
Time Frame:42 days
Safety Issue:
Description:Hematologic and non-hematologic toxicities will be tabulated.

Secondary Outcome Measures

Measure:Response rate (complete remission [CR], CR with incomplete blood count recovery [CRi], partial remission [PR] or stable disease [SD]) using LeukemiaNet guidelines
Time Frame:Up to 6 months
Safety Issue:
Description:Proportions of these patients in each response category will be tabulated; the combined proportion in categories CR, CRi, PR, and SD will be computed along with an exact 95% confidence interval.
Measure:Response duration
Time Frame:From start of induction, assessed up to 6 months
Safety Issue:
Description:Summarized using a Kaplan-Meier plot.
Measure:Early mortality
Time Frame:From start of induction, assessed up to 6 months
Safety Issue:
Description:Summarized using a Kaplan-Meier plot.

Details

Phase:Phase 1
Primary Purpose:Interventional
Overall Status:Terminated
Lead Sponsor:Stanford University

Last Updated